Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6111]

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced ovarian cancer

ASCO 2023: Addition of olaparib and durvalumab prolonged progression-free survival in patients with advanced...

ASCO 2023: Changes in RECIST tumour measures correlate linearly with survival in patients treated with checkpoint inhibitors

ASCO 2023: Changes in RECIST tumour measures correlate linearly with survival in patients treated with checkpoint...

ASCO 2023: Adding ribociclib to hormonal therapy reduces risk of recurrence for people with most common subtype of breast cancer

ASCO 2023: Adding ribociclib to hormonal therapy reduces risk of recurrence for people with most common subtype of...

ASCO 2023: Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with paclitaxel

ASCO 2023: Taxane-induced peripheral neuropathy in breast cancer: Frequent, clinically significant, and worse with...

ASCO 2023: Thyroid cancer precision approaches that incorporate targeted therapies and other treatments are changing the surgeon’s role

ASCO 2023: Thyroid cancer precision approaches that incorporate targeted therapies and other treatments are...

Personalising prostate cancer screening may improve the accuracy of detection

Personalising prostate cancer screening may improve the accuracy of detection

Researchers use “deep sequencing” to identify several previously undescribed genetic variants in vascular anomalies

Researchers use “deep sequencing” to identify several previously undescribed genetic variants in vascular anomalies

New data informs treatment of blood cancer during pregnancy

New data informs treatment of blood cancer during pregnancy

Initiative will test new drug combinations guided by tumour biology

Initiative will test new drug combinations guided by tumour biology

FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated mCRPC

FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated mCRPC

More from ecancer